BIOSANTE PHARMACEUTICALS TO PRESENT POSITIVE STUDY RESULTS FOR POTENTIAL ADJUVANTED BIRD FLU VACCINE

BioSante Pharmaceuticals, Inc. today announced that it will present positive results of several pre-clinical studies, demonstrating that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant, may serve as an adjuvant for the development of an effective flu virus vaccine, including the potentially pandemic H5N1 bird flu.
Genetic Engineering News